
    
      These study results present the possibility that imatinib can be used as a new DME inhibiting
      agent by involving VEGF-independent ocular angiogenesis, not action points of existing
      agents, in effectively inhibiting excessive vascular angiogenesis observed in oxygen-induced
      retinopathy.
    
  